Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:INAB NASDAQ:PHIO NASDAQ:PPCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$2.82-1.4%$3.14$2.15▼$4.69$12.32M1.5520,754 shs2,690 shsINABIN8bio$1.20+0.8%$1.46$1.17▼$2.73$11.82M0.2248,690 shs30,214 shsPHIOPhio Pharmaceuticals$1.04-2.8%$1.05$0.81▼$4.19$12.43M0.811.56 million shs81,888 shsPPCBPropanc Biopharma$1.37-5.5%$1.66$1.30▼$270.25$3.30M3.493.07 million shs13,245 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-1.40%-2.76%-16.32%+24.78%-38.16%INABIN8bio+0.84%-9.77%-18.91%-20.00%-51.22%PHIOPhio Pharmaceuticals-2.80%+0.97%+1.96%-12.61%-59.06%PPCBPropanc Biopharma-5.52%-8.05%-8.05%-50.14%-98.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$2.82-1.4%$3.14$2.15▼$4.69$12.32M1.5520,754 shs2,690 shsINABIN8bio$1.20+0.8%$1.46$1.17▼$2.73$11.82M0.2248,690 shs30,214 shsPHIOPhio Pharmaceuticals$1.04-2.8%$1.05$0.81▼$4.19$12.43M0.811.56 million shs81,888 shsPPCBPropanc Biopharma$1.37-5.5%$1.66$1.30▼$270.25$3.30M3.493.07 million shs13,245 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-1.40%-2.76%-16.32%+24.78%-38.16%INABIN8bio+0.84%-9.77%-18.91%-20.00%-51.22%PHIOPhio Pharmaceuticals-2.80%+0.97%+1.96%-12.61%-59.06%PPCBPropanc Biopharma-5.52%-8.05%-8.05%-50.14%-98.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 1.00SellN/AN/AINABIN8bio 2.00Hold$4.00233.33% UpsidePHIOPhio Pharmaceuticals 2.00Hold$14.001,246.15% UpsidePPCBPropanc Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PPCB, PHIO, INAB, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/4/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/1/2026PPCBPropanc Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$1.40M8.79N/AN/A$5.36 per share0.53INABIN8bioN/AN/AN/AN/A$2.82 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/APPCBPropanc BiopharmaN/AN/AN/AN/A$29.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$1.17M-$1.92N/AN/AN/A-563.70%-37.73%-19.42%8/13/2026 (Estimated)INABIN8bio-$19.44M-$2.61N/AN/AN/AN/A-96.39%-80.18%8/6/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)PPCBPropanc Biopharma-$58.92M-$24.25N/AN/AN/AN/A-151.28%-109.53%N/ALatest PPCB, PHIO, INAB, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026BLRXBioLineRx-$0.15N/AN/AN/A$0.43 millionN/A8/13/2026Q2 2026PHIOPhio Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/6/2026Q2 2026INABIN8bio-$0.3437N/AN/AN/AN/AN/A5/27/2026Q1 2026BLRXBioLineRx-$1.04-$0.36+$0.68N/A$0.34 million$0.48 million5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/A5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.161.581.43INABIN8bioN/A10.5010.50PHIOPhio PharmaceuticalsN/A18.3218.32PPCBPropanc BiopharmaN/A2.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%INABIN8bio92.05%PHIOPhio Pharmaceuticals57.31%PPCBPropanc BiopharmaN/AInsider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%INABIN8bio14.50%PHIOPhio Pharmaceuticals0.89%PPCBPropanc Biopharma28.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.37 million4.32 millionOptionableINABIN8bio209.85 million8.42 millionNot OptionablePHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionablePPCBPropanc Biopharma12.28 million1.63 millionNot OptionablePPCB, PHIO, INAB, and BLRX HeadlinesRecent News About These CompaniesPropanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed JournalJuly 21, 2026 | globenewswire.comPropanc Biopharma Signs MOU with Avance Clinical Pty LtdJuly 7, 2026 | globenewswire.comPropanc Biopharma launches $5M share repurchase programJuly 2, 2026 | msn.comPropanc Biopharma Initiates $5.0 Million Share Repurchase ProgramJuly 2, 2026 | globenewswire.comPropanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH StudyJune 16, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH StudyJune 16, 2026 | globenewswire.comPPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?June 13, 2026 | finance.yahoo.comPropanc Biopharma Authorizes $5.0 Million Share Repurchase ProgramJune 11, 2026 | globenewswire.comPropanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an ...June 2, 2026 | caledonianrecord.comCPropanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, SpainJune 2, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, SpainJune 2, 2026 | globenewswire.comPropanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeMay 20, 2026 | markets.businessinsider.comPropanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeMay 20, 2026 | globenewswire.comPropanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer PatientsMay 19, 2026 | globenewswire.comPropanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate DevelopmentsMay 15, 2026 | quiverquant.comQPropanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 ResultsMay 15, 2026 | globenewswire.comPropanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq ComplianceMay 13, 2026 | quiverquant.comQPropanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansMay 13, 2026 | globenewswire.comPropanc Biopharma Inc.April 24, 2026 | barrons.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCBApril 17, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026KBR Insiders Are Buying While the Market Misreads Its SpinoffBy Thomas Hughes | July 6, 2026GE Sparks a High-Voltage Aviation BreakoutBy Jeffrey Neal Johnson | July 22, 2026IBM Just Had Its Worst Day Ever—What Earnings Must ProveBy Chris Markoch | July 21, 2026PPCB, PHIO, INAB, and BLRX Company DescriptionsBioLineRx NASDAQ:BLRX$2.82 -0.04 (-1.40%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$2.98 +0.17 (+5.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.IN8bio NASDAQ:INAB$1.20 +0.01 (+0.84%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.20 0.00 (-0.42%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. Phio Pharmaceuticals NASDAQ:PHIO$1.04 -0.03 (-2.80%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.02 -0.02 (-1.44%) As of 07/24/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Propanc Biopharma NASDAQ:PPCB$1.37 -0.08 (-5.52%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.38 +0.01 (+1.02%) As of 07/24/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
